|
15.06.2018 02:30:00
|
Kyros Law is Investigating Claims on Behalf of Invokana users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Filed.
BOSTON, June 14, 2018 /PRNewswire/ -- Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking compensation for their injuries. According to a February 22nd filing with the U.S. & Securities and Exchange Commission, Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceuticals unit have been named defendants in approximately 1,100 lawsuits involving Invokana.
Invokana users that suffered serious side effects while taking Invokana are urged to contact our law firm immediately to protect their rights. Visit our Invokana Side Effect Lawsuit webpage or call 1-800-934-2921 to speak to someone about your case.
Hundreds of Invokana lawsuits have been centralized in the U.S. District Court, District of New Jersey, with hundreds of additional Invokana lawsuits pending in various state courts. These lawsuits allege that users of Invokana suffered serious side effects such as Diabetic Ketoacidosis, Kidney Injury, Limb Amputations and Heart Complications.
Kyros Law Offices urges Invokana users that suffered serious side effects while taking Invokana to contact our law firm immediately to protect their rights. Visit our Invokana Side Effect Lawsuit webpage or call 1-800-934-2921 to speak to someone about your case.
Receive alerts about other potential class action lawsuits that may affect you by visiting the Class Action Lawsuit Center website.
Kyros Law specializes in a wide range of complex litigation, mass torts, and corporate governance matters, including the representation of whistleblowers, shareholders and consumers in securities fraud, false claims act and class actions. Our lawyers have been responsible for recovering hundreds of millions of dollars for our clients throughout the United States, Africa, Asia and Europe. Visit our website to learn more about our firm.
View original content:SOURCE Kyros Law
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
|
05.03.25 |
Zuversicht in New York: Dow Jones am Nachmittag freundlich (finanzen.at) | |
|
05.03.25 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel Gewinn hätte ein Investment in Johnson Johnson von vor 10 Jahren eingebracht (finanzen.at) | |
|
04.03.25 |
Minuszeichen in New York: Dow Jones zum Start des Dienstagshandels im Minus (finanzen.at) | |
|
03.03.25 |
Verluste in New York: Dow Jones fällt zum Ende des Montagshandels zurück (finanzen.at) | |
|
03.03.25 |
Schwacher Handel in New York: Dow Jones sackt am Montagnachmittag ab (finanzen.at) | |
|
03.03.25 |
Schwacher Handel in New York: Dow Jones verliert (finanzen.at) | |
|
27.02.25 |
Freundlicher Handel in New York: Dow Jones am Donnerstagmittag mit Zuschlägen (finanzen.at) | |
|
27.02.25 |
Handel in New York: Dow Jones startet im Plus (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
| Johnson & Johnson | 153,38 | 0,42% |
|
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.